Showing results (21-30 of 196) with videos related to

Sort By:
Pageof 20
Plos One|July 13, 2017
Characterization of a panel of monoclonal antibodies recognizing specific epitopes on GFAPNi-Hsuan Lin, Albee Messing, Ming-Der Perng
International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience|August 15, 2002
GFAP mutations in Alexander diseaseRong Li, Albee Messing, James E Goldman, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 1, 2010
Strategies for treatment in Alexander diseaseAlbee Messing, Christine M LaPash Daniels, Tracy L Hagemann
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|February 5, 2016
An In Vivo Pharmacological Screen Identifies Cholinergic Signaling as a Therapeutic Target in Glial-Based Nervous System DiseaseLiqun Wang, Tracy L Hagemann, Albee Messing, et al.
Experimental Cell Research|May 15, 2007
GFAP and its role in Alexander diseaseRoy A Quinlan, Michael Brenner, James E Goldman, et al.
BMC Research Notes|December 25, 2012
The effect of glial fibrillary acidic protein expression on neurite outgrowth from retinal explants in a permissive environmentKimberly A Toops, Tracy L Hagemann, Albee Messing, et al.
Human Molecular Genetics|January 9, 2009
Suppression of GFAP toxicity by alphaB-crystallin in mouse models of Alexander diseaseTracy L Hagemann, Wilbert C Boelens, Eric F Wawrousek, et al.
Glia|June 15, 2010
Alteration of glial-neuronal metabolic interactions in a mouse model of Alexander diseaseTore Wergeland Meisingset, Øystein Risa, Michael Brenner, et al.
Neurochemical Research|January 25, 2005
Expression specificity of GFAP transgenesMu Su, Huimin Hu, Youngjin Lee, et al.
The Journal of Biological Chemistry|February 23, 2017
Glial fibrillary acidic protein exhibits altered turnover kinetics in a mouse model of Alexander diseaseLaura R Moody, Gregory A Barrett-Wilt, Michael R Sussman, et al.
Pageof 20